Translacijska istraživanja u neuroznanosti

Šimić, Goran

Conference presentation / Izlaganje na skupu

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:105:021171

Rights / Prava: In copyright/Zaštićeno autorskim pravom.

Download date / Datum preuzimanja: 2024-05-13



Repository / Repozitorij:

<u>Dr Med - University of Zagreb School of Medicine</u> <u>Digital Repository</u>



Translacijska istraživanja u neuroznanosti

Goran Šimić Medicinski fakultet Sveučilišta u Zagrebu



Sažetak izlaganja

 Osvrt na razvitak ideje o važnosti translacijskog pristupa istraživanjima u neuroznanosti

 Neki novi časopisi orijentirani na objavljivanje rezultata translacijskih istraživanja

• Časopis Translational Neuroscience

Brojna nova otkrića, ali bez (brze) dobrobiti za bolesnike

mef.hr

translacijska istraživanja

Translacijska istraživanja Alzheimerove bolesti jučer, danas i sutra

Što smo prije dvadeset godina znali o Alzheimerovoj bolesti (AB) i kako smo je liječili?


S obzirom na nastanak AB, od njezina prvog opisa pa do današnjih dana bilo je rasprostranjeno vjerovanje o postojanju jedinstvenog uzročnika bolesti. To se svojstvo osamdesetih i devedesetih godina pripisivalo isključivo amiloidu, kao središnjem činitelju u nastanku AB, a mogući slijed događaja koji dovode do bolesti nazvan je amiloidnom kaskadnom hipotezom.

Sve do 1991. godine većina znanstvenika, čak i onih koji su se aktivno bavili proučavanjem AB, nije vjerovala da ova bolest čiji se simptomi i znakovi pojavljuju tako kasno u tijeku života može nastati zbog jednog jedinog "krivog" slova u genomu koji broji nekoliko milijardi slova. Tada je pronađena prva mutacija gena za amiloidni prekursorni protein – APP (tzv. Londonska mutacija). Do danas je

treba odmah reći da je i danas liječenje simptomatsko, a ne uzročno. Razvoi i registracija lijekova uobičajeno kasne za znanstvenim spoznajama, u prosjeku 10 - 15 godina. Otkada su Whitehouse i suradnici dokumentirali propadanje bazalne jezgre (čiji se neuroni projiciraju u moždanu koru, a koriste neurotransmiter acetilkolin) u oboljelih od AB 1981. godine, smatralo se da bi se pospješenjem dielovanja acetilkolina moglo liječiti AB. Trebalo je 12 godina do registracije takrina 1993., 16 godina do registracije donepezila 1997., 19 godina do registracije rivastigmina 2000., odnosno 20 godina do registracije galantamina 2001. godine. U međuvremenu je jasno pokazano. da je propadanje živčanih stanica bazalne iezgre samo sekundarna i relativno kasna posljedica propadanja živčanih stanica u moždanoj kori, pa ne čudi činjenica da ti lijekovi samo prolazno i kratkotrajno usporavaju napredovanje bolesti, i to samo u nekih bolesnika u početnim stadilima bolesti.

postjedica normalnog starenja, ne može dokazati ako se u analizu ne ukliuče i mlade odrasle osobe. S druge strane, kad se na gubitak neurona koji pripisujemo samom starenju pridoda broj neurofibrilarnih snopiča u AB, neka područja mozga, kao što su hipokampus i entorinalni korteks, pokazuju veći gubitak neurona nego što bi se on mogao objasniti samo neurofibrilarnim promjenama. To je dokaz da u AB postoje različiti mehanizmi propadanja živčanih stanica. Jedan od ključnih problema jest i činjenica da je gotovo nemoguće razviti dobar životinjski model za proučavanje bolesti koja ie karakteristična za čovieka, a traje 20 - 30 godina prije nastanka prvih kliničkih simptoma. Ne tako davno svjedočili smoda je nedostatak temelinih spoznaja o mehanizmima nastanka AB rezultirao katastrofalnim neuspiehom pokušaja liječenia bolesti imunizacijom 360 bolesnika cijelom molekulom beta-amiloida (vakcina AN1792). Zbog aktivacije potpornih stanica te upale mozga i moždanih ovojnica umrlo je tridesetak bolesnika uklju-

Lancet Neurol 2010; 9: 702-16



Svi su se navedeni spojevi:

- Pokazali obećavajućima u eksperimentalnim istraživanjima na životinjama
- Pokazali obećavajućima u prvoj fazi kliničkih istraživanja (na malom broju ispitanika)
- ALI...
 se nakon toga moralo odustati od njihove daljnje primjene
- ZAŠTO (i kako su uspjeli proći sve prethodne faze)?

Glavni razlozi za neuspjeh translacije istraživanja u nove načine liječenja su:

 Upotreba životinjskih modela bolesti koji ne odražavaju dovoljno precizno patogenezu dotičnih bolesti u ljudi

2. Činjenica da je mala vjerojatnost objavljivanja negativnih, nesignifikantnih ili neutralnih rezultata dobivenih u predkliničkim istraživanjima

Translational and Clinical Science — Time for a New Vision

Elias A. Zerhouni, M.D.

N ENGL J MED 353;15 WWW.NEJM.ORG OCTOBER 13, 2005

- ... "At no other time has the need for a bidirectional information flow between basic and translational scientists been so necessary."
- ... "Genomics, proteomics, transgenic animal models, structural biology, biochemistry, and imaging technologies offer unprecedented prospects for advancing knowledge of human disorders in a translational context"
- ..."In an attempt to address these concerns, ... the NIH has funded facilities, resources, or both (...36% of its budget) to bolster translational research. ...Yet, the concerns persist, and more must be done."
- ..."The scope of knowledge and expertise needed to be an effective translational scientist can no longer be aquired "on the job", as was done in the past."

Lost in Translation

Facing Up to Translational Research

James Levine

DIABETES, VOL. 56, DECEMBER 2007

- ..."Currently, in science, we have our buzz word: "translational research"...Whichever academic center you visit and whatever despairing grant review panel you sit on, I guarantee that the term "translational research" will surface. In fact, I bet that somewhere on earth at every second of every day, somebody somewhere is using the term "translational research" because they are tacitly aware of the fact that there is an urgent need to think out of the box..."
- ..."The wonderful thing about translational research is that every one knows exactly what it means – the only trouble is that none of them have the same definition."
- ..."linear, hypothesis-driven research is almost extinct; ...hypotheses now represent observing the effect of 10,000 genes on scenario X or examining how 50,000 proteins respond to soup Y?... Perhaps, I should turn off the computer and toss my PDA if it will give me the time to do what I am supposed to do as a scientist: take a look at the world and think."


GUEST EDITORIAL

Translational Research 2008;151:57-58.

Translational research in environmental health sciences

- ..."Clearly, a need exists to translate more quickly the myriad of discoveries in biomedical research into more effective applications relevant to human health and disease."
- ..."Translating research and patient data should be viewed as an interconnecting and multidirectional network, with information that flows back and forth among basic scientists, clinicians, epidemiologists, engineers, and policy makers."
- ..."The concept of translational research is not meant to push academic scientists into starting biotech companies or to be totally product driven. Translation should be viewed as both an opportunity and in some ways an obligation, so that the general public receives some tangible benefit for supporting the vast research enterprise."
- ..."The importance of translational research relative to the broad research enterprise is perhaps best summed up by the following quote from Goethe: "Knowing is not enough; we must apply. Willing is not enough; we must do.""

Translational Medicine



Translational Psychiatry



About the journal Open access For authors Contact editorial office For librarians Advertising Reprints and permissions Contact NPG

Customer services Site features

2011 | Volume 1

			Apr	May	<u>Jun</u>
<u>Jul</u>	Aug	<u>Sep</u>	<u>Oct</u>	Nov	Dec

Introducing the journal "Translational Neuroscience"

Although the last two decades have brought an amazingly rapid accumulation of information concerning all aspects of neuroscience, promising applications of this expanding knowledge have only slowly being realized. In other words, there has been an unprecedented necessity to translate more quickly the discoveries in biomedical research into more effective applications relevant to human health and disease.

With this in mind, several of my colleague scientists, and here I wish to thank particularly Professor Patrick R. Hof from Mount Sinai School of Medicine in New York (now the Senior Advisory Editor of the journal) and myself started to think of responding to this real need in the scientific community by launching a journal devoted to translational neuroscience. After several months of discussions, at the beginning of this year we launched the journal "Translational Neuroscience". The journal is published by Versita and co-published by Springer Verlag publishers.


"Translational Neuroscience" is an international peer-reviewed journal published quarterly in paper (p-ISSN 2081-3856) and electronic (e-ISSN 2081-6936) versions. The language of the journal is English. The web site of the journal is http://www.versita.com/science/medicine/tn.

I'm pleased to let you know that Springer has approved to begin distributing the journal "Translational Neuroscience" worldwide from 2011 and will also host the 2010 volume on SpringerLink http://www.springerlink.com. I welcome all submissions, comments and suggestions you might have in order to improve our Journal.


Sincerely,

Goran Šimić, M.D., Ph.D. Translational Neuroscience, Editor-in-Chief and Managing Editor


Translational Neuroscience




Translational Neuroscience



Translational Neuroscience




Translational Neuroscience indeksiranost



Abstracts, BIOSIS, OCLC, SCImago, Summon by Serial Solutions

Literature Selection Technical Research Committee



List of Titles Scheduled for June 21-22, 2012 LSTRC Review

Data as of May 30, 2012

NOTE: If a link does not lead directly to the journal content, use the link in the Reviewer Web Form.

Electronic titles will say [electronic] immediately after the title.


- 160. Revista Portuguesa De Farmacoterapia
- 161. Semergen / Sociedad Espanola De Medicina Rural Y Generalista
- 162. Spermatogenesis
- 163. Student Bmj
- 164. Sykepleien Forskning
- 165. Thehealth
- 166. Therapeutic Delivery
- 167. Tianjin Yi Yao = Tianjin Medical Journal
- 168. Tijdschrift Voor Neurologie & Neurochirurgie
- 169. TraditSionnaiA MeditSina
- 170. Translational Neuroscience
- 171. Trends In Biomaterials & Artificial Organs
- 172. Trends In Food Science & Technology
- 173. Turk Gogus Kalp Damar Cerrahisi Dergisi
- 174. US Cardiology
- 175. Western Pacific Surveillance And Response Journal: Wpsar [electronic]
- 176. Wiley Interdisciplinary Reviews. Computational Molecular Science
- 177. World Journal Of Clinical Oncology [electronic]
- 178. World Journal Of Microbiology & Biotechnology
- 179. Zhongguo Wei Sheng Tai Xue Za Zhi
- 180. Zhonghua Fang She Xue Za Zhi Chinese Journal Of Radiology

Hvala na pažnji!





springer.com



Translational Neuroscience

Translational Neuroscience is an international, peer-reviewed journal that considers articles from all fields of neuroscience, as well as from related disciplines of neurology, psychiatry and neurosurgery.

The aim of this journal is to provide a closer interaction between basic and clinical neuroscientists by publishing original papers that expand our understanding of brain structure, function, and disease, and translate this knowledge into clinical applications and novel therapies of nervous system disorders.

Review articles are also encouraged and sometimes invited, as well as constructive and interesting correspondence. The journal is published quarterly in English language.

On the homepage of Translational Neuroscience at springer.com you can

- Read the most downloaded articles for free
- Sign up for our Table of Contents Alerts
- Get to know the complete Editorial Board
- Find submission information